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INTRODUCTION
Although chronic graft-versus-host disease (cGVHD)
has a beneficial graft-versus-leukemia effect, it also has a
detrimental effect on the long-term outcome and quality of
life following allogeneic blood and marrow transplantation
(BMT). Despite efforts to decrease the incidence and sever-
ity of acute GVHD, cGVHD has emerged as an increas-
ingly frequent complication of BMT, due to increased use
of mismatched and unrelated donors [1] and, recently, the
use of allogeneic peripheral blood as a source of hemato-
poietic stem cells [2-4].
Our recent data on 151 patients showed that the median
cGVHD-speciﬁc survival was 11.4 years after the diagnosis
of cGVHD [5]. However, the probability of long-term sur-
vival in patients with poor prognostic features, such as
extensive (>50%) skin involvement, thrombocytopenia
(<100 K/mm3), poor performance status (Karnofsky perfor-
mance score <50%), and progressive type of onset, was
<20% once they failed primary therapy [5]. Although a vari-
ety of new drugs have come to the market and are currently
being tested, only minor progress has been made in the
treatment of progressive or refractory cGVHD. Once
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ABSTRACT
Corticosteroids remain essential for controlling active chronic graft-versus-host disease (cGVHD). However, the
optimum dose and administration schedule is unknown. We have reviewed our results in 61 patients with severe
refractory cGVHD who were treated with a high-dose pulse steroid regimen (PS) consisting of methylprednisolone
at 10 mg/kg per day for 4 consecutive days, with subsequent tapering doses. After 4 days, all patients received a
course of additional immunosuppressive therapy. The median age of the 56 patients who were evaluable for
response was 32 years (range, 0.2-57 years). Patients had failed a median of 2 (range, 1-5) treatments prior to the
PS. The median follow-up for 45 surviving patients after PS was 1.5 years. The probability of survival at 1 year and
2 years after PS was 88% (95% confidence interval [CI], 76%-95%) and 81% (95% CI, 65%-91%), respectively.
Twenty-seven patients (48%) showed a major response to PS with substantial improvement of cGVHD manifesta-
tions, including softening of the skin, increased range of motion, and improved performance status; 15 patients
(27%) showed a minor response, defined as improvement in some but not all symptoms of cGVHD. Of the
42 responders, 21 (50%) had progression of their cGVHD afterwards. The median time to progression was
1.9 years. The probability of progression at 1 and 2 years after PS was 36% (95% CI, 23%-53%) and 54% (95% CI,
38%-71%), respectively. The probability of progression at 1 year was 25% (95% CI, 12%-47%) and 55% (95% CI,
32%-81%) for patients who had major and minor response, respectively (hazard ratio, 2.13). Ten of the 42 respon-
ders (24%) were able to discontinue all systemic immunosuppressive treatments. The probability of discontinuation
at 1 and 2 years after PS was 9% (95% CI, 3%-25%) and 27% (95% CI, 15%-48%), respectively. The treatment was
well tolerated with no serious adverse events. Our results suggest that PS is a well-tolerated regimen for achieving
rapid clinical response in the majority of patients with cGVHD who failed on multiple previous therapies. Further
studies are warranted to maintain the efficacy of this regimen by combining with new active agents in cGVHD.
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cGVHD has progressed after the initial therapies of cyclo-
sporine and prednisone [6], the strategy of subsequent
treatment is not well established.
Corticosteroids with or without other immunosuppres-
sive agents such as FK-506 (tacrolimus) [7] or cyclosporine
[6] still remain the mainstay of therapy for cGVHD. How-
ever, the optimum dose, administration schedule, and type
of corticosteroid treatment for controlling the acute pro-
gression of GVHD are unknown. Although several reports
compare 10 mg/kg per day with lower doses of glucocorti-
coids in the up-front treatment of acute GVHD [8-10], no
consensus has been reached about the optimum high-dose
glucocorticoid regimen in GVHD. There are also no data
about the role of a high-dose corticosteroid regimen in the
treatment of cGVHD. The utility of pulses of steroids in
cGVHD has not been reported.
In rheumatology and clinical immunology, acute flares
or particularly severe forms of rheumatic diseases, such as
systemic lupus erythematosus, vasculitis, polymyositis, and
rheumatoid arthritis, are examples of the successful use of
high-dose glucocorticoid therapy, usually 10 to 15 mg/kg
per day times 3 days. Pulse therapy results in termination
of the exacerbation or regression of a severe form of dis-
ease in a high proportion of cases, with a relatively low
incidence of side effects.
The following high-dose pulse steroid (PS) regimen that
we describe has always been a standard approach in control-
ling severe refractory cGVHD at Johns Hopkins. This
report summarizes our experience with this PS regimen in
cGVHD. It examines the question of whether response to
PS is predictive of response to future therapy, ability to con-
trol cGVHD leading to discontinuation of all immunosup-
pressive treatments, and survival.
PATIENTS AND METHODS
Patients
Between February 1988 and June 1999, 61 patients with
clinicopathologic diagnosis of active cGVHD refractory to
previous systemic immunosuppressive therapies were
treated with a PS regimen followed by an immunosuppres-
sive therapy protocol that was active in our institution at
that time. The majority of patients were referred from other
centers to our GVHD clinic for the management plan.
Patient characteristics are summarized in Table 1. Five
patients who were lost to follow-up after receiving PS
therapy were not included in the analyses. The median age
of 56 patients who were evaluable for response was 32 years
(range, 0.2-57 years). Stem cell donors were HLA-identical
siblings in 40 patients (72%), HLA-identical unrelated
donors in 12 patients (21%), and 1-antigen mismatched sib-
ling donor in 4 patients (7%). The source of stem cell was bone
marrow in 52 patients (93%) and blood in 4 patients (7%).
One patient received a nonmyeloablative HLA-identical
bone marrow transplant. The clinical diagnosis of cGVHD
had to be conﬁrmed by clinical ﬁndings and histopathology
of the skin in all patients and, if indicated, liver or mucous
membrane biopsies before the PS therapy. Other cGVHD-
related features are shown in Table 2.
PS Treatment Regimen
Step 1 (Days 1 Through 4). Patients diagnosed as hav-
ing cGVHD, either flared after responding to a course of
immunosuppressive therapy or progressed while on therapy,
received PS treatment consisting of high-dose pulse methyl-
prednisolone at 10 mg/kg per day given either orally or
intravenously for 4 consecutive days (Figure 1). All dosing
was based on actual body weight.
Step 2 (Day 5 and Onward). Patients completing a
4-day high-dose PS regimen were started on a new systemic
immunosuppressive therapy, which was decided by the insti-
tutional protocol active at that time (Table 3). Patients who
were receiving a corticosteroid prior to the PS therapy were
restarted on the same dose of steroid they were previously
on and gradually tapered off over 4 weeks. Mostly, the PS
treatment was administered under the supervision of
patients’ local oncologists in their hometowns. All adverse
effects occurring during the PS administration and within
the 1-month period following the treatment were retrieved.
For patients showing improvement, the new immuno-
suppressive regimen was continued according to the proto-
col or until cGVHD progression. Patients who had no
response to PS plus their new immunosuppressive regimen
Table 1. Patient Characteristics (N = 56)*
n (%)
Median age 32 y (range, 0.2-57 y)
Male/female 33/23 (59/41)
Underlying diseases
Chronic myelogenous leukemia 17 (29)
Acute myeloid leukemia 15 (27)
Acute lymphoblastic leukemia 6 (10)
Aplastic anemia 5 (9)
Multiple myeloma 4 (7)
Non-Hodgkin’s lymphoma 2 (4)
Myelodysplastic syndrome 2 (4)
Paroxysmal nocturnal hemoglobinuria 1 (2)
Thalassemia 1 (2)
Fanconi anemia 1 (2)
Myelofibrosis 1 (2)
Chronic granulomatous disease 1 (2)
Donor type
HLA-identical, related 40 (72)
HLA-identical, unrelated 12 (21)
One antigen mismatch 4 (7)
Source of graft
Bone marrow 52 (93)
Blood 4 (7)
Transplantation date
1988-1993 28 (50)
1994-1999 28 (50)
GVHD prophylaxis 35†
Cyclosporine alone 16 (46)
Cyclosporine + methotrexate ± ATG 7 (20)
Cyclosporine + methotrexate + prednisone ± ATG 4 (11)
Cyclosporine + prednisone 4 (11)
T-cell depletion 1 (3)
Others 3 (9)
*GVHD indicates graft-versus-host disease; ATG, antithymocyte
globulin.
†Denominator indicates number of patients for whom data were
present.
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after 3 months of therapy and those who subsequently pro-
gressed after the initial response to PS were treated with
another salvage regimen during their follow-up. PS was not
repeated in patients who failed on the initial attempt.
Study Definitions
Response. Response was evaluated based on the changes
in signs and symptoms of skin, joint, liver, mouth, eye, and
other cGVHD involvement by clinical criteria. Each organ
was evaluated for response an overall response was deter-
mined. The following deﬁnitions of response were used.
Major response: Complete resolution or unequivocal
improvement in all of the cGVHD signs and symptoms
after PS while on immunosuppressive therapy. Signs and
symptoms were measured against scores obtained at baseline
evaluation. Patients had to show improvement in 1 or more
systems scores and have no signs of ﬂare in others.
Minor response: Improvement in some disease signs and
symptoms but progression or no change in others while on
immunosuppressive therapy. Patients had to show improve-
ment in 1 or more organ systems while worsening (ﬂare) or
having no change in others.
No response: Increase or no improvement in any disease
signs or symptoms despite immunosuppressive therapy.
Patients had to have ﬂare in 1 or more organ systems with-
out a response in any other. Failure to improve in any mani-
festation of cGVHD was also considered as failure to
Table 2. Characteristics of cGVHD at Diagnosis*
n (%)
Type of cGVHD 55†
Progressive 12 (22)
Quiescent 20 (36)
De novo 23 (42)
Histology of cGVHD 54†
Lichenoid 22 (41)
Sclerodermatous ± lichenoid 32 (59)
Biopsy sites for cGVHD diagnosis‡ 37†
Skin 30 (70)
Oral cavity 9 (21)
Liver 4 (8)
Extent of skin involvement 49†
No skin involvement 6 (12)
≤50% body surface area 14 (29)
>50% body surface area 29 (59)
Number of risk factors at diagnosis§ 49†
None 16 (33)
1 or 2 31 (63)
3 2 (4)
*cGVHD indicates chronic graft-versus-host disease.
†Denominator indicates number of patients for whom data were
present. 
‡Six patients had >1 biopsy site. 
§Risk factors at diagnosis [5]: extensive skin involvement (>50%),
platelets ≤100.000/µL, and progressive-type onset.
Figure 1. High-dose pulse methylprednisolone (PS) regimen used at Johns Hopkins. cGVHD indicates chronic graft-versus-host disease; PO, by
mouth; IV, intravenous; GI, gastrointestinal; d/c, discontinuation; QD, every day; TID, 3 times a day; PS, high-dose pulse steroid regimen.
*Current infectious proplaylaxis used for paitents with cGVHD.
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respond, even when there was no worsening of the symp-
toms and signs of cGVHD.
Progression. Progression of cGVHD was defined as
clinically worsening, active cGVHD compared with the
signs and symptoms of cGVHD at the beginning of PS
therapy. The clinical criteria for progression were stopping
the immunosuppressive regimen that was started immedi-
ately after PS and instituting another regimen in full dose to
control the cGVHD progression.
Statistical Analysis
The major statistical end points of this study were
response, time to progression, and time to discontinuation
of all systemic immunosuppressive therapies after PS. For
categorical predictors, response rates were compared using
chi-square tests or Fisher exact tests when data were sparse.
Continuous predictive factors were tested using logistic
regression. Event times were measured in years from the
ﬁrst day of PS therapy to time of cGVHD progression, dis-
continuation of all systemic immunosuppressive treatment,
death, and/or last follow-up. Survival was defined as the
time until death or last follow-up. The overall survival
analysis included all patients. Only patients who were con-
sidered responders were included in the time to progression
and discontinuation of immunosuppression analyses and ﬁg-
ures. Time to progression was defined as the time until
cGVHD progression or last follow-up. Deaths without pro-
gression were censored using the longest follow-up time for
the time to progression analysis and showed separately as a
competing risk. Time to discontinuation of all treatment
was deﬁned as the time from the PS treatment until the date
of discontinuation of all systemic immunosuppressive thera-
pies. Deaths without discontinuation were censored using
the longest follow-up time for the time to discontinuation
analysis and showed separately as a competing risk. The
death as a competing risk analyses exclude deaths after pro-
gression or discontinuation of immunosuppression. The
probabilities of survival, progression, and discontinuation of
all systemic immunosuppressive therapies were estimated
using the Kaplan-Meier method [11]. Point estimates are
given ±95% confidence bounds [12]. The data were ana-
lyzed as of June 29, 2001, using STATA 6.0.
RESULTS
Of 61 patients, 56 were evaluable for response. Five
patients who received PS treatment were lost to follow-up
and therefore not included in analysis. Patients were started
on PS therapy after failing a median of 2 treatment regi-
mens/courses (range, 1-5 courses) given over a median of
12.5 months (range, 2-94 months) after the initial diagnosis
of cGVHD. Patients received a median of 11 months
(range, 1-94 months) of systemic corticosteroid with or
without other immunosuppressive agents prior to PS
(Tables 3 and 4). The median dosage of prednisone that
patients were taking at the time of PS was 0.2 mg/kg per day
(range, 0-2.5 mg/kg per day) (Table 4). Fifty-four patients
(96%) received PS mainly because of severe cutaneous
cGVHD. One patient had progressive liver and oral
cGVHD and another had bronchiolitis obliterans.
Table 3. Immunosuppressive Regimens Used in the Treatment of cGVHD
(N = 56)*
Regimen n (%)
Initial treatment for cGVHD at diagnosis
Prednisone only 7 (12)
Cyclosporine + prednisone ± PUVA 32 (57)
FK-506 + prednisone 5 (9)
FK-506 + MMF 2 (4)
Cyclosporine + prednisone + azathioprine 5 (9)
Cyclosporine + prednisone + thalidomide ± PUVA 1 (2)
Others 4 (7)
Treatment immediately prior to PS
Prednisone only 6 (11)
Adjunctive therapy only† 7 (13)
Cyclosporine + prednisone ± adjunctive therapy 12 (22)
Cyclosporine + prednisone + thalidomide 
± adjunctive therapy 4 (7)
Cyclosporine + prednisone + azathioprine 
± adjunctive therapy 4 (7)
FK-506 + MMF + prednisone 14 (25)
Photopheresis 3 (5)
Others 5 (9)
Unidentified 1 (2)
Treatment following PS
FK-506 + MMF + steroid (taper) ± etretinate 20 (36)
FK-506 + steroid ± etretinate 8 (14)
Cyclosporine + prednisone + etretinate 14 (25)
Cyclosporine + prednisone + thalidomide 6 (11)
Pentostatin + steroid (taper) 3 (5)
Others 5 (9)
*cGVHD indicates chronic graft-versus-host disease; PUVA, pso-
ralen and ultraviolet A light; MMF, mycophenolate mofetil; PS, high-
dose pulse steroid regimen.
†Adjunctive therapies included topical corticosteroids, PUVA,
etretinate, clofozamine, and plaquenil.
Table 4. Previous Treatment of cGVHD*
Number of treatment regimens prior to PS, n (%) n = 54†
1 11 (22)
2 17 (31)
3 14 (25)
4 9 (16)
5 3 (6)
Total duration of previous treatments, mo n = 49†
Median (range) 12.5 (2-94)
Total duration of previous steroid treatment, mo n = 49†
Median (range) 11 (1-94)
Dosage (mg/kg per day) of prednisone immediately n = 49† 
prior to PS, n (%)
0 12 (25)
0-0.5 26 (53)
0.5-1.0 5 (10)
1.0-1.5 4 (8)
>1.5 2 (4)
Median (range), mg/kg per day 0.2 (0-2.5)
*cGVHD indicates chronic graft-versus-host disease; PS, high-dose
pulse steroid regimen.
†Denominator indicates number of patients for whom data were
present. 
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Response to Therapy
Overall, 42 patients (75%) were classiﬁed as responders
and 14 (25%) as nonresponders, as shown in Figure 2.
Twenty-seven patients (48%) showed a major response to
PS with substantial resolution of all cGVHD manifestations,
including softening of the skin, increased range of motion,
and improved performance status. Fifteen patients (27%)
showed a minor response. Univariate analysis did not iden-
tify any clinical parameter predictive of response. There was
no difference in achieving response between the 2 groups of
patients (70% and 83%) who were and were not on corti-
costeroids just before PS therapy. The proportion of nonre-
sponders/responders was also not different by age, sex,
donor type, stem cell source, type of onset of cGVHD, and
duration of prior cGVHD treatments including corticos-
teroids. In addition, we could not ﬁnd a statistically signiﬁ-
cant correlation between the dose of corticosteroid that
patients received prior to the PS and response. The patient
with bronchiolitis obliterans did not respond to PS.
Survival
As of June 29, 2001, 45 of the 56 patients are alive with
a median follow-up of 1.5 years. The probability of survival
at 1 year and 2 years after PS was 88% (95% confidence
interval [CI], 76%-95%) and 81% (95% CI, 65%-91%),
respectively (Figure 3).
Time to Failure (Progression of cGVHD)
Of the 42 responders, 21 (50%) had subsequent pro-
gression of their cGVHD. Six responders (14%) died with-
out having documented progression. The main causes of
death in these patients were late infections complicated by
multiorgan failure (n = 4), pulmonary emboli (n = 1), and
unknown (n = 1). The median time to progression was 1.9
years. The probability of progression at 1 year and 2 years
after PS was 36% (95% CI, 23%-53%) and 54% (95% CI,
38%-71%), respectively (Figure 4). The probability of death
as a competing risk at 1 and 2 years was 10% (95% CI, 4%-
25%) and 15% (95% CI, 6%-34%), respectively. The haz-
ard ratio comparing minor versus major response was 2.13.
The probability of progression at 1 year was 25% (95% CI,
12%-47%) and 55% (95% CI, 32%-81%) for patients who
had major and minor response, respectively.
Discontinuation of Immunosuppressive Therapy
Ten of the 42 (24%) responders discontinued systemic
immunosuppressive treatment at one point after PS. Seven
responding patients died before discontinuation because of
infection with (n = 3) or without (n = 4) progressive
cGVHD. Another patient died of respiratory failure sec-
ondary to bronchiolitis obliterans. The probability of discon-
tinuation of systemic immunosuppressive therapy at 1 year
and 2 years after PS was 9% (95% CI, 3%-25%) and 27%
(95% CI, 15%-48%), respectively (Figure 5).
Adverse Effects
All patients tolerated the PS regimen very well, without
any life-threatening adverse effects. Two patients had a
hypertensive episode and another developed tachycardia
associated with dizziness during PS administration. None of
these events necessitated hospitalization. After the comple-
tion of PS, 1 patient who had hypertension and 2 other
patients (5%) later developed various infections, including
Figure 2. Response to high-dose pulse steroid regimen in 56 patients.
Figure 3. Kaplan-Meier probability of survival for all patients.
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cellulitis and disseminated herpes simplex (n = 1), pneumo-
nia (n = 1), and aspergillus (n = 1). These 3 patients were
already on steroids and other immunosuppressive drugs.
DISCUSSION
The optimal dose and schedule of corticosteroid treat-
ment in aborting the acute progression of cGVHD are
unknown and clinical data are very limited. Although vari-
ous doses of systemic corticosteroids have been used in
acute GVHD [8-10], there has been no study evaluating the
role of high-dose corticosteroid regimens in the treatment
of cGVHD. In a small study, 2 of 7 patients with acute
GVHD responded to high-dose glucocorticoid therapy
when the dosage was escalated from 5 mg/kg per day to
10 mg/kg per day [9]. This dose-response relation was
not demonstrated in another study when the comparison
was made between the dosages of 2 mg/kg per day and
10 mg/kg per day [10]. Although high-dose glucocorticoid
therapy is a well-accepted initial treatment for a variety of
immunologically mediated diseases, including GVHD, the
question of what dose of steroid should be considered high
still remains to be determined.
The concept of the PS regimen was to use a lympholytic
dose of steroids to try to destroy as many effector lympho-
cytes as possible before permanent tissue damage occurred.
Glucocorticoids have different mechanisms of action
depending on their dose. Low-dose glucocorticoids achieve
their action completely by classic genomic effects, mediated
by the glucocorticoid receptor. In addition to these well-
known genomic effects, high doses of glucocorticoids inter-
fere, via nongenomic pathways, with the process of energy
metabolism crucial for the immediate and sustained activa-
tion of lymphocytes. Buttgereit and his colleagues have
Figure 4. Kaplan-Meier probability of progression and survival after high-dose pulse methylprednisolone therapy in responding patients with
chronic graft-versus-host disease (cGVHD).
Figure 5. Kaplan-Meier probability of discontinuation (d/c) of all systemic immunosuppressive therapy and survival after high-dose pulse methyl-
prednisolone therapy in responding patients with chronic graft-versus-host disease.
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assessed the relative therapeutic importance of these nonge-
nomic effects in pulse corticosteroid therapy by measuring
the number of glucocorticoid receptor sites and glucocorti-
coid receptor binding afﬁnity in peripheral blood mononu-
clear cells isolated from 48 healthy children and 35 patients
[13]. The patients had been divided into 3 groups based on
glucocorticoid treatment: 0 mg/kg (group 1), 0.01 to
0.3 mg/kg orally (group 2), and 10 to 15 mg/kg intravenous
pulse therapy (group 3) of prednisolone equivalent per day.
The number of receptor sites in patients without glucocorti-
coid treatment (group 1) was signiﬁcantly lower than that of
healthy volunteers. This value was further reduced in
patients receiving glucocorticoid treatment. The more
signiﬁcant downregulation of receptor binding sites (group
3) was found after pulse therapy compared with untreated
patients. These results have conﬁrmed the previous observa-
tion in another study population reported by the same
investigators [14]. It was suggested that pulse therapy doses
of glucocorticoids that exceed receptor saturation have an
additional effect on lymphocytes via significant receptor
downregulation (nongenomic effect).
Other studies have shown that high-dose glucocorticoid
treatment could diminish or prevent the acute immune
response by interfering with processes, such as the rise in
intracellular Ca2+ concentration, that are essential for the
immediate and sustained activation of lymphocytes [15]. High
doses of glucocorticoids affect both the activated and the
resting cell populations. It has been previously demonstrated
in thymocytes that glucocorticoid pretreatment of resting/
quiescent cells prevents the concanavalin A–induced increase
of oxygen consumption and rise in cytosolic Ca2+. Conse-
quently, quiescent glucocorticoid-treated cells are less likely
to become activated during the course of the disease [16,17].
High-dose PS therapy may also turn off the lymphocyte
functions through the induction of apoptotic mechanisms. In
a recent study from Japan, investigators evaluated the in vivo
effects of high-dose (1 g) methylprednisolone infusion on
peripheral blood T-lymphocyte apoptosis induction in
patients with severe autoimmune diseases [18]. DNA frag-
mentation was detected in peripheral blood T cells isolated
from these patients after 2 and 4 hours of steroid infusion. In
contrast, T cells isolated from the same patients before or
8 or more hours after infusion did not show DNA fragmen-
tation. To support the T-cell apoptosis induction by high-
dose PS therapy, peripheral blood T cells from normal subjects
underwent DNA fragmentation after in vitro exposure to
2.5 to 10 µg/mL of methylprednisolone for 30 minutes.
The results of the present study suggest that methyl-
prednisolone treatment at 10 mg/kg for 4 days can lead to a
major improvement of symptoms and signs in approximately
half of the patients with severe refractory cGVHD. We have
observed a high response rate (75%) using our PS regimen in
cGVHD patients who were refractory to a median of 2 pre-
vious systemic immunosuppressive treatment courses.
Although median time to progression of cGVHD after PS
was about 2 years with occasional durable responses, subse-
quent progression or ﬂare of cGVHD is concerning, particu-
larly in those who had no or minor response to PS. Although
this PS regimen was initially effective in reversing the
cGVHD progression, it was not capable of switching off
cGVHD completely in the majority of patients. At 3 years
after PS therapy, the probability of progression was 61%,
proving that long-term control of cGVHD is clearly needed.
Perhaps the most important point of this study is the
correlation between the type of response to PS and time to
progression. The 30% difference in the probability of pro-
gression at 1 year after PS therapy between patients who
achieve major response and those who achieve minor
response suggests that better response is associated with
longer time to progression. This may provide some impor-
tant prognostic information for patients and physicians.
PS therapy usually was tolerated excellently, with very
few immediate side effects. However, the infectious complica-
tions occurring in 3 patients after completing the therapy
raise the possibility of profound immunosuppression, which
may be associated with the PS regimen on top of already
heavily immunosuppressed patients. It will remain unknown
whether PS therapy itself or the subsequent new immunosup-
pressive therapy course is the primary set-up for the occur-
rence of these infections seen within 1 month of therapy.
The PS protocol we report here is based on the clinical
experience we have gained over the past 12 years in treating
patients with cGVHD. Our previous results support the use
of PS over a short treatment time because little additional
beneﬁt could be obtained by a longer treatment duration or
higher doses. As noted in this report, the majority of our
patients, particularly those who had major responses to PS,
had sustained resolution of GVHD activity. Median time to
progression was almost 2 years in those who responded to
PS and a subsequent course of immunosuppressive treat-
ment. One could argue that the time to progression may
also be related to the effectiveness of the immunosuppres-
sive treatment given after PS. This is certainly a possibility,
but it is not likely due to the lack of data showing that any
particular salvage regimen is superior to another in the set-
ting of progressive cGVHD.
In summary, our results demonstrate that PS is an
effective and well-tolerated regimen in patients with pro-
gressive/refractory cGVHD. Timely identiﬁcation of non-
responding or incompletely responding patients may allow
early assignment to alternate immunosuppressive treat-
ment. The early combination of PS with other treatment
strategies including monoclonal antibodies [19-22] may
further improve response rate and progression-free survival
of some patients. Additional studies are warranted to test
this hypothesis.
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